Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
59.24 EUR | -1.40% | +3.42% | +0.44% |
May. 13 | Eurofins Scientific to Expand US Battery Materials Testing Capabilities | MT |
May. 13 | Eurofins Scientific expands capacity in the USA | CF |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company is in debt and has limited leeway for investment
- With a 2024 P/E ratio at 29.26 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company is not the most generous with respect to shareholders' compensation.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.44% | 12.59B | A- | ||
+19.22% | 85.64B | C+ | ||
-27.14% | 70.63B | B- | ||
+4.65% | 27.05B | C+ | ||
-6.23% | 17.97B | B | ||
+1.60% | 17.58B | A- | ||
+3.30% | 15.64B | A- | ||
+7.44% | 13.55B | B- | ||
+9.91% | 13.41B | A- | ||
+73.32% | 13.18B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ERF Stock
- Ratings Eurofins Scientific SE